MannKind Corporation  

(Public, NASDAQ:MNKD)   Watch this stock  
Find more results for MNKD
+0.10 (7.04%)
May 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.30 - 1.68
52 week 0.67 - 6.50
Open 1.42
Vol / Avg. 6.83M/5.07M
Mkt cap 164.34M
P/E 1.11
Div/yield     -
EPS 1.37
Shares 95.78M
Beta 3.30
Inst. own 19%
May 19, 2017
Mannkind Corp Annual Shareholders Meeting (Estimated)
May 10, 2017
Q1 2017 MannKind Corp Earnings Call - Webcast
Mar 16, 2017
Q4 2016 MannKind Corp Earnings Call
Mar 16, 2017
Q4 2016 MannKind Corp Earnings Release
Mar 13, 2017
MannKind Corp at ROTH Conference - Webcast
Mar 1, 2017
MannKind Corp Extraordinary Shareholders Meeting
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin -542.51% 71.91%
Operating margin -651.45% 79.70%
EBITD margin - 38.33%
Return on average assets -68.12% 107.65%
Return on average equity - -
Employees 153 -
CDP Score - -


25134 Rye Canyon Loop Ste 300
VALENCIA, CA 91355-5031
United States - Map
+1-661-7755300 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a portable inhaler. AFREZZA utilizes its Technosphere formulation technology. Technosphere is a drug delivery platform that may allow the oral inhalation of a range of therapeutics. Technosphere powders are based on the Company's fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created a range of breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format.

Officers and directors

Kent Kresa Chairman of the Board
Age: 78
Bio & Compensation  - Reuters
Matthew Jonathan Pfeffer CPA. Chief Executive Officer, Chief Financial Officer, Director
Age: 57
Bio & Compensation  - Reuters
Rose Alinaya Senior Vice President, Principal Accounting Officer
Age: 54
Bio & Compensation  - Reuters
Linda Adreveno Senior Vice President - Human Resources
Age: 60
Bio & Compensation  - Reuters
Joseph Kocinsky Chief Technology Officer, Corporate Vice President
Age: 52
Bio & Compensation  - Reuters
David B. Thomson Ph.D., J.D. Corporate Vice President, General Counsel, Corporate Secretary
Age: 49
Bio & Compensation  - Reuters
Michael E. Castagna Pharm.D. Corporate Vice President, Chief Commercial Officer
Age: 39
Bio & Compensation  - Reuters
Raymond W. Urbanski M.D., Ph.D. Corporate Vice President, Chief Medical Officer
Age: 57
Bio & Compensation  - Reuters
Stuart A. Tross Ph.D. Chief People Officer
Age: 49
Bio & Compensation  - Reuters
James Samuel Shannon M.D. Director
Age: 59
Bio & Compensation  - Reuters